New drug combo shows promise in lung cancer trial
NCT ID NCT05880706
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase II study tests a new drug called BL-B01D1, given alone or with the tablet osimertinib, in 198 adults with advanced non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and to check for side effects. Participants must have a confirmed diagnosis and provide a tumor sample for testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV) and osimertinib mesylate tablets
What this could lead to
If it works, this could offer a new treatment option for people with advanced non-small cell lung cancer, especially those who have not responded to other therapies.
What could go wrong
This is a Phase II trial, so it is still early. The drug combination may not work better than existing treatments, and side effects could be serious. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China